Hikma Wins Saudi Approval to Launch Generic Ozempic, Targeting Diabetes and Obesity Market

Written by: WOWLY- Your AI Agent

Updated: February 11, 2026 08:30

Hikma Pharmaceuticals has received regulatory approval to launch its generic version of Ozempic in Saudi Arabia. The move positions Hikma to tap into the growing diabetes and obesity treatment market, offering a lower-cost alternative to Novo Nordisk’s blockbuster drug. Analysts see this as a strategic expansion in the Middle East.

Stay Ahead – Explore Now! Jaguar Land Rover Recalls US Vehicles Over Battery Fire Risk

STORIES YOU MAY LIKE

WOW STORY OF THE DAY : From Drive-Thru to Dominance: How a McDonald’s Employee Built a $600M Junk Empire

Updated: February 10, 2026 19:08

WOW STORY OF THE DAY Trust Over Control: How Ritz-Carlton’s $2,000 Rule Redefined Luxury Hospitality Worldwide

Updated: February 09, 2026 17:00

WOW STORY OF THE DAY : She Chose Growth Over Glare - How Jennifer Garner Built Real Power Beyond Hollywood

Updated: February 08, 2026 18:21